Factors Associated With Loss of Fecal Biomarker Accuracy During Routine Assessment of Inflammatory Bowel Disease

Documenti analoghi

• Compounding Prevalence of Inflammatory Bowel Disease in a 2024 Population‐Based Study From Canterbury, New Zealand
  di: Angela J. Forbes, et al.
  Pubblicazione: (2025)
• Therapeutic Drug Monitoring of Vedolizumab Levels During Maintenance in Inflammatory Bowel Disease ( MOVE ‐ IBD )
  di: Hayley Logan, et al.
  Pubblicazione: (2026)
• The Association Between Atopic Dermatitis and Inflammatory Bowel Disease Risk: A Meta‐Analysis of Longitudinal Studies
  di: Pengfei Yu, et al.
  Pubblicazione: (2024)
• Effect of Tissue Eosinophilia on the Disease Outcome of Pediatric With Inflammatory Bowel Disease (IBD)
  di: Arefeh Zahmatkesh, et al.
  Pubblicazione: (2025)
• Loss of Response to Anti‐Tumor Necrosis Factor Alpha Therapy in Patients With Inflammatory Bowel Disease: A Real‐World Comparison of Combination Therapy Versus Monotherapy
  di: Faris Chater, et al.
  Pubblicazione: (2026)